JinMatrix Receives MFDS Manufacturing Approval for New HPV Diagnostic Kit Product

JinMatrix Human Papillomavirus Diagnostic Product.

[Asia Economy Reporter Lee Gwan-joo] JinMatrix announced on the 11th that it has obtained manufacturing approval from the Ministry of Food and Drug Safety for its new human papillomavirus (HPV) diagnostic product, 'NeoPlex HPV29 Detection.'

JinMatrix's new NeoPlex product is based on the proprietary 'C-Tag' technology and enables simultaneous multiplex diagnosis of 29 types of human papillomavirus, the causative virus of cervical cancer, in a single test. Its excellent sensitivity and specificity have been proven through large-scale clinical trials.

Compared to existing products, the analysis time has been reduced by more than one hour, allowing results to be obtained within two hours. It accurately identifies viral genotypes according to the risk level of cervical cancer, achieving high test accuracy.

A JinMatrix official stated, “The adoption of HPV DNA testing in the field of cervical cancer diagnosis is becoming a global standard of care. Based on the advantages of the NeoPlex product, which is easy, fast, and accurate, we will expand our market share in the domestic and international molecular diagnostics markets amid the growing market.”